Company logo

ANVS - Annovis Bio, Inc.

NYSE -> Healthcare -> Biotechnology
Berwyn, United States
Type: Equity

ANVS price evolution
ANVS
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $4 $3.14 $5.75
Short term investments
Net receivables
Inventory
Total current assets $14.36 $5.05 $7.81 $10.21
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $14.36 $5.05 $7.81 $10.21
Current liabilities
Accounts payable $4.1 $3.39 $4.11 $1.29
Deferred revenue
Short long term debt
Total current liabilities $5.39 $4.06 $4.87 $4.28
Long term debt
Total noncurrent liabilities $2.74 $6.3 $13.68
Total debt
Total liabilities $7.3 $6.8 $11.17 $17.96
Shareholders' equity
Retained earnings -$128.98 -$116.35 -$111.33 -$110.26
Other shareholder equity
Total shareholder equity -$1.75 -$3.35 -$7.75
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 30 Jan 2021
Current assets
Cash $5.75 $28.38 $45.69 $8.07
Short term investments
Net receivables
Inventory
Total current assets $10.21 $36.02 $46 $8.12
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $10.21 $36.02 $46 $8.12
Current liabilities
Accounts payable $1.29 $3.96 $0.69 $0.34
Deferred revenue
Short long term debt
Total current liabilities $4.28 $7.7 $1.51 $0.58
Long term debt
Total noncurrent liabilities $13.68
Total debt
Total liabilities $17.96 $7.7 $1.51 $0.58
Shareholders' equity
Retained earnings -$110.26 -$54.05 -$28.73 -$14.24
Other shareholder equity $0
Total shareholder equity -$7.75 $28.32 $44.49 $7.54
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $5.79 $6.51 $8.9
Selling, general & administrative $1.98 $1.29 $1.54
Total operating expenses $7.76 $7.81 $10.44
Operating income -$7.76 -$7.81 -$10.44
Income from continuing operations
EBIT -$5.02 -$1.07 -$22.21
Income tax expense
Interest expense
Net income
Net income -$5.02 -$1.07 -$22.21
Income (for common shares) -$5.02 -$1.07 -$22.21
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 30 Jan 2021
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $38.79 $16.52 $8.48
Selling, general & administrative $6.24 $9 $6.06
Total operating expenses $45.04 $25.51 $14.54 $6.64
Operating income -$45.04 -$25.51 -$14.54 -$6.64
Income from continuing operations
EBIT -$56.2 -$25.33 -$14.49
Income tax expense
Interest expense
Net income
Net income -$56.2 -$25.33 -$14.49 -$5.46
Income (for common shares) -$56.2 -$25.33 -$14.49
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$5.02 -$1.07 -$22.21
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation $1.6 $0.36 $0.88
Total cash flows from operations -$3.38 -$7.03 -$9.36
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock $4.24 $4.42 $8.76
Net borrowings
Total cash flows from financing $20.49 $4.24 $4.42 $8.76
Effect of exchange rate
Change in cash and equivalents $6.88 $0.86 -$2.62 -$0.6
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 30 Jan 2021
Net income -$56.2 -$25.33 -$14.49 -$5.46
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation $4.63 $9.15 $4.7
Total cash flows from operations -$39.97 -$17.31 -$9.13 -$3.97
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock $17.34 $0 $46.74
Net borrowings
Total cash flows from financing $17.34 $0 $46.74 $12.04
Effect of exchange rate
Change in cash and equivalents -$22.62 -$17.31 $37.61 $8.07
Fundamentals
Market cap $66.55M
Enterprise value N/A
Shares outstanding 13.28M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity -2.32
Net debt/EBITDA N/A
Current ratio 2.66
Quick ratio N/A